Science Court

Scientists are "not immune to the currently seductive ideologies," as Arthur Kantrowitz asserts in his Opinion piece of Feb. 2, 1998 (The Scientist, 12[3]:9). There has been a clear shift from the "idea of progress," when every new or possible technology was uncritically hailed, to the current period, in which the balance of doubt and skepticism has shifted. I mark the shift with Rachel Carson's Silent Spring (Boston, Houghton Mifflin, 1962). But the wondrous quality of what most of us share a

Written byRobert Kates
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

But the wondrous quality of what most of us share as scientists is that while we may be selectively attracted to one set of conjectures vs. another by how we think or might want the world to be, eventually those give way to new theories, and finally evidence--or the lack of it--manifests itself in our willingness to acknowledge ignorance. When such ignorance persists despite our best efforts, many of us accept the relevance of ethics, law, economics, or politics for adjudication or, more commonly, compromise.

I do remember Kantrowitz's early efforts to propose a science court and thought them interesting, novel, and worth trying. A few years ago, I got my chance to participate in one organized by the Federation of American Scientists to help inform the World Bank about a policy related to global warming. I came away much discouraged by the experience. The litigious, adversarial nature of the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies